Development of nano structured graphene oxide incorporated dexamethasone with enhanced dissolution
Source abstract
Abstract
We present the development of nanographene oxide (nGO) incorporated dexamethasone (DXM) composites (DXM-nGO) with enhanced aqueous solubility. Antisolvent precipitation was used for successful incorporation of nGO into DXM, a popular COVID-19 drug. The study focuses on morphology and dissolution performance of the formulated DXM-nGO, which were characterized using scanning electron microscopy (SEM), Raman spectroscopy, X-ray diffraction (XRD), Differential scanning calorimetry (DSC) and Thermogravimetric analysis (TGA). In vitro dissolution profile showed that for a DXM-nGO containing 0.5% nGO showed that time for 50% dissolution (T50) dropped from 39 min to 24 min, while time for 80% dissolution (T80) went from not dissolved state to 56 min for the same composite. In general, the nGO incorporation into DXM showed enhanced solubility, and in vitro dissolution data suggest that the nGO may be a candidate for successful bioavailability improvement.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Graphene and Nanomaterials Applications · Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (40)
Show source-provided references
1. Physicochemical characterization of drug nanocarriers10.2147/IJN.S133832 ↗
2. Engineering biodegradable nanoparticles for drug and gene delivery
3. Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
4. Nanotechnology in therapeutics. A focus on nanoparticles as a drug delivery system10.2217/nnm.12.87 ↗
5. Therapeutic nanoparticles and their targeted delivery applications10.3390/molecules25092193 ↗
6. Clay nanoparticles as pharmaceutical carriers in drug delivery systems10.1080/17425247.2021.1862792 ↗
7. Montmorillonite nanoclay as a multifaceted drug-delivery carrier: a review10.1016/j.jddst.2017.03.023 ↗
8. Comprehensive review on graphene oxide for use in drug delivery system10.2174/13816128256661902011296290 ↗
9. Functionalized graphene oxide as a vehicle for targeted drug delivery and bioimaging applications10.1039/D0TB01149E ↗
10. Derivatives of graphene oxide as potential drug carriers10.1166/jnn.2019.15855 ↗
11. New insights into the solubility of graphene oxide in water and alcohols10.1039/C7CP02303K ↗
12. A comparative study of particle size distribution of graphene nanosheets synthesized by an ultrasound-assisted method10.3390/nano9020152 ↗
13. Engineering precision nanoparticles for drug delivery10.1038/s41573-020-0090-8 ↗
14. Nanostructured polymer composites for biomedical applications. Ch.22 - graphene oxide for drug delivery and cancer therapy
15. Development of a graphene oxide-poly lactide nanocomposite as a smart drug delivery system10.1016/j.ijbiomac.2020.12.084 ↗
16. The future development of bacteria fighting medical devices: the role of graphene oxide10.1080/17434440.2016.1245612 ↗
17. Graphene oxide-PLGA hybrid nanofibers for the local delivery of IGF-1 and BDNF in spinal cord repair10.1080/21691401.2019.1575843 ↗
18. Graphene and graphene oxide as nanomaterials for medicine and biology application10.1007/s40097-018-0265-6 ↗
19. Direct incorporation of nano graphene oxide (nGO) into hydrophobic drug crystals for enhanced aqueous dissolution10.1016/j.colsurfb.2020.110827 ↗
20. Antisolvent precipitative immobilization of micro and nanostructured griseofulvin on laboratory cultured diatom frustules for enhanced aqueous dissolution
21. In vivo biodistribution and toxicology of functionalized nano-graphene oxide in mice after oral and intraperitoneal administration10.1016/j.biomaterials.2013.01.001 ↗
22. Enhanced antitumor activity of bovine lactoferrin through immobilization onto functionalized nano graphene oxide: an in vitro/in vivo study10.1080/10717544.2020.1809558 ↗
23. Nano-graphene oxide-mediated In vivo fluorescence imaging and bimodal photodynamic and photothermal destruction of tumors10.1016/j.biomaterials.2016.04.006 ↗
24. VEGFR targeting leads to significantly enhanced tumor uptake of nanographene oxide in vivo10.1016/j.biomaterials.2014.10.061 ↗
25. Cellular uptake of mildly oxidized nanographene for drug-delivery applications10.1021/acsanm.9b02035 ↗
26. Intravenous delivery of enzalutamide based on high drug loading multifunctional graphene oxide nanoparticles for castration-resistant prostate cancer therapy10.1186/s12951-020-00607-4 ↗
27. Delivery of paclitaxel using PEGylated graphene oxide as a nanocarrier10.1021/am507798d ↗
28. The biopharmaceutics classification system: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC10.1016/j.ejps.2014.01.009 ↗
29. Applying biopharmaceutical classification system (BCS) criteria to predict oral absorption of drugs in dogs: challenges and pitfalls10.1208/s12248-015-9743-7 ↗
30. Solubility enhancement of BCS Class II drug by solid phospholipid dispersions: Spray drying versus freeze-drying10.1016/j.ijpharm.2015.10.029 ↗
31. Challenges to improve the biopharmaceutical properties of poorly water-soluble drugs and the application of the solid dispersion technology
32. Combinative particle size reduction technologies for the production of drug nanocrystals
33. Stabilizing agents for drug nanocrystals: effect on bioavailability10.3390/pharmaceutics8020016 ↗
34. Dexamethasone for the treatment of coronavirus disease (COVID-19): a review
35. Dexamethasone in hospitalized patients with Covid-1910.1056/NEJMoa2021436 ↗
36. Center for drug evaluation and research | CDER, Application number: 211379Orig1s000
37. Cruanes · 2013
38. Nanoengineered drug releasing titanium wires as an alternative for local delivery of chemotherapeutics in the brain
39. Differential scanning calorimetry: an invaluable tool for a detailed thermodynamic characterization of macromolecules and their interactions10.4103/0975-7406.76463 ↗
40. Multipoint dissolution specification and acceptance sampling rule based on profile modeling and principal component analysis10.1080/10543409708835198 ↗